AMORFIX LIFE SCIENCES APPOINTS DR. WALTER VON WARTBURG TO BOARD OF DIRECTORS
AND ENHANCES BUSINESS DEVELOPMENT ACTIVITIES
TSX: AMF
TORONTO, Oct. 20 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases including Alzheimer's disease (AD) and cancer, announced today that Dr. Walter von Wartburg, currently Partner in private law practice and Executive Chairman of Medgate AG, a leading provider of medical information services, has been appointed to the Board of Directors.
Dr. von Wartburg has held senior management positions within the global pharmaceutical industry including Roche, Ciba-Geigy and Novartis for over 20 years, specializing in US/EU regulatory affairs for drug and medical devices. He is professor of public health policy at the Saint Gall Graduate School of Economics, Business and Public Administration, a law graduate of the Universities of Basel, Paris, Princeton, Stanford and Harvard Law School, and author of books and articles on subjects ranging from drug legislation, social acceptance of gene technology, and issues of management and business administration.
Dr. von Wartburg is Founder-President of the Swiss Foundation for the mentally handicapped "PRO MENTE SANA", a member of the Bioethics Institute Advisory Committee of Johns Hopkins University, President of the Basel Opera and Theatre and Co-chairman of the International culture Foundation PRO EUROPA.
Philippe Couillard, Chairman of the Amorfix Board of Directors, commented, "We are very pleased to welcome Dr. von Wartburg to the Company's Board. Walter's vast experience in the areas of pharma, business and science will be a great addition to the expertise of our current Board for the development of our innovative pipeline of therapeutics and diagnostics for misfolded protein diseases."
In addition, the company also announced that it has engaged Posada & Associates, Inc. to assist the company with business strategy and partnering transactions. James Posada, Ph.D., MBA will support the management team and Board in assessing and executing on its partnering goals. "Jim brings years of experience and an incredible track record of successful business deals with both big pharma and biotech organizations," said Dr. Robert Gundel, President and CEO of Amorfix. "I am excited to work with Jim as an important member of the Amorfix team to advance our business development activities for discovery platform technology deals, out-licensing programs and strategic partnerships for product development."
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's disease, ALS, and cancer. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated Beta-Amyloid (ABeta) in brain tissue and blood from animal models of AD, months prior to observable amyloid formation, as well as human blood screening tests for Alzheimer's and early liver cancer detection. Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSE") on the molecular surface of misfolded proteins. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, AD and cancer. For more information about Amorfix, visit www.amorfix.com.
%SEDAR: 00022789E
For further information:
Dr. Robert Gundel President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 [email protected] |
Janet Clennett Acting Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6926 Fax: (416) 847-6899 [email protected] |
Share this article